Home Transfusion Program Components for Malignancies, Hematologic

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dana-Farber Cancer Institute, Boston, MA
Malignancies, Hematologic+2 More
Home Transfusion Program Components - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions

Eligible Conditions

  • Malignancies, Hematologic

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Malignancies, Hematologic

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 6 months

3 Weeks
Satisfaction Rate
6 months
Completion of Home Transfusions and Patient-Reported Data
Disenrollment Rate
Enrollment Rate

Trial Safety

Safety Progress

1 of 3

Other trials for Malignancies, Hematologic

Trial Design

1 Treatment Group

Home Transfusion
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Home Transfusion Program Components · No Placebo Group · N/A

Home Transfusion
Other
Experimental Group · 1 Intervention: Home Transfusion Program Components · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Dana-Farber Cancer Institute · Boston, MA
Photo of Boston 1Photo of Boston 2Photo of Boston 3
2007First Recorded Clinical Trial
12 TrialsResearching Malignancies, Hematologic
923 CompletedClinical Trials

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,008 Previous Clinical Trials
393,026 Total Patients Enrolled
15 Trials studying Malignancies, Hematologic
5,845 Patients Enrolled for Malignancies, Hematologic
Oreofe O Odejide, MD, MPHPrincipal InvestigatorDana-Farber Cancer Institute

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction.
You are an informal caregiver of an enrolled patient with hematologic malignancy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.